Get the Stockscreener App
27.90
1.27%
-0.36
After Hours:
27.75
-0.15
-0.54%
Arcutis Biotherapeutics Inc stock is traded at $27.90, with a volume of 802.45K.
It is down -1.27% in the last 24 hours and up +4.65% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$28.26
Open:
$28.05
24h Volume:
802.45K
Relative Volume:
0.46
Market Cap:
$3.49B
Revenue:
$415.62M
Net Income/Loss:
$-2.38M
P/E Ratio:
-982.39
EPS:
-0.0284
Net Cash Flow:
$16.92M
1W Performance:
+0.43%
1M Performance:
+4.65%
6M Performance:
+4.69%
1Y Performance:
+91.75%
1-Day Range:
$27.69
$28.46
1-Week Range:
$27.32
$28.98
52-Week Range:
$13.70
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
27.90 | 3.53B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
472.57 | 122.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
651.18 | 70.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.72 | 54.72B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.03 | 38.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
266.99 | 36.23B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
META_TITLE_QUOTE - Yahoo Finance
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,730 common shares worth $127,269.30 - Bitget
Form 4 Arcutis Biotherapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options - Stock Titan
Arcutis Biotherapeutics director sells $127,284 in stock - Investing.com
Arcutis Biotherapeutics (ARQT) director trades stock under 10b5-1 plan - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup - ChartMill
Arcutis appoints Christopher Peetz to its board as Class III director - TradingView
Arcutis Biotherapeutics (Nasdaq: ARQT) names Chris Peetz to its board - Stock Titan
Arcutis Biotherapeutics, Inc. Appoints Christopher Peetz to its Board of Directors, Effective July 15, 2026 - marketscreener.com
Arcutis Biotherapeutics appoints Chris Peetz to board - Investing.com
Arcutis appoints Chris Peetz to its Board to bo... - Pluang
Arcutis Expands Board of Directors with Appointment of Chris Peetz - The Manila Times
Arcutis Biotherapeutics appoints Chris Peetz to board By Investing.com - Investing.com Canada
Attovia Therapeutics appoints John Smither to board By Investing.com - Investing.com Australia
Arcutis to report Q2 2026 financial results on August 5 - scanx.trade
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 - The Manila Times
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares - Stock Titan
Arcutis schedules Aug. 5 webcast for its business update - Stock Titan
FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com Nigeria
Arcutis gets FDA review for Zoryve 0.05% label expansion - MSN
Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies - The Globe and Mail
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
FDA accepts Arcutis application for infant eczema treatment - Investing.com
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo
FDA accepts Arcutis' application to expand ZORY... - Pluang
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times
Arcutis wins FDA review for ZORYVE in infants as young as 3 months - Stock Titan
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Arcutis Biotherapeutics (ARQT) Rises 4.6% as Biotech Sector Momentum Drives Shares HigherResistance Breakout Stocks - dars.gov.et
Price to sales forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Price to earnings forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Enterprise value to EBITDA forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
3 Healthcare Stocks Built For Higher Rates And Steady Demand - Sahm
Arcutis Biotherapeutics (ARQT) Edges Lower, Tests Key Support Levels Amid ConsolidationEquity Put Call - dars.gov.et
Comparative Analysis of Arcutis and Vertex Biotherapeutics - Intellectia AI
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - The Motley Fool
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis lures 9 new hires with 61,000 stock awards - Stock Titan
Arcutis grants 61,000 RSUs to new hires under Nasdaq rule - scanx.trade
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis launches virtual dermatology platform for skin conditions By Investing.com - Investing.com India
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcutis Biotherapeutics Inc Stock (ARQT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Welgus Howard G. | Director |
Jul 15 '26 |
Sale |
26.91 |
4,730 |
127,284 |
37,109 |
1.36%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):